中文摘要：热杀性牝牛分枝杆菌(Mv)能够激发CD8(+) 和CD4(+) T细胞反应，具有佐剂特性。研究将Mv与MTO结合构建了一种新型佐剂MTOM。将结核融合蛋白Rv3407-PhoY2-Ag85A-Rv2626c-RpfB (WH121)与MTO、Mv、MTOM混合构建了三种亚单位疫苗，以C57BL/6小鼠为对象比较了这三种疫苗的保护效率和免疫反应。结果表明，WH121/MTOM能够提供更好的保护作用，MTOM更能提高单功能或多功能IL-2(+) T细胞浓度、诱导Th1-型免疫反应方面。因此，MTOM可作为结核亚单位疫苗的有效佐剂进行推广应用。
 
外文摘要： The only licensed vaccine Mycobacterium bovis Bacillus Calmette-Guerin (BCG) cannot prevent the prevalence of tuberculosis (TB), which remains a major public health problem worldwide. A more effective TB vaccine than BCG is urgently needed. Subunit vaccine is a promising strategy, and suitable adjuvants will benefit the development of effective TB subunit vaccines. MTO, consisting of monophosphoryl lipid A (MPLA), trehalose-6,6'-dibehenate (TDB), and MF59, was developed as an adjuvant of TB vaccine because of its ability to evoke the Th1-type T cell responses, while it is insufficient to induce single and multifunctional IL-2(+) T cells and has a limited ability to confer protection against Mycobacterium tuberculosis infection. Heat-killed Mycobacterium vaccae (Mv), which can evoke cytotoxic CD8(+) and CD4(+) T cell responses and has adjuvanticity, was, in this study, combined with MTO to produce a new adjuvant, called MTOM. The TB fusion protein Rv3407-PhoY2-Ag85A-Rv2626c-RpfB (WH121) was mixed with MTO, Mv, and MTOM to produce three subunit vaccines, and the protective efficacy and immune responses were compared in C57BL/6 mice. WH121/MTOM provided better protection against TB than the other two vaccines, matching the performance of BCG vaccine. MTOM showed stronger ability to increase single and multifunctional IL-2(+) T cells and induce Th1-type responses than MTO or Mv. Therefore, MTOM might be a promising adjuvant that could contribute to the development of TB subunit vaccines.
外文关键词：adjuvant; MTOM; Mycobacterium tuberculosis; Th1-type response; IL-2(+) T cells
作者：Yu, Q; Wang, XC; Fan, XL
作者单位：华中农业大学
期刊名称：FRONTIERS IN IMMUNOLOGY
期刊影响因子：5.695
出版年份：2017
出版刊次：5
点击下载：一种新型佐剂MTOM能够调控结核分歧杆菌亚单位疫苗增强Th1型T细胞免疫反应和IL-2(+) T细胞浓度